Faeth Therapeutics (FTH) Q3 2026 earnings review
Faeth wins FDA fast track, but its quarterly spending climbs
Faeth Therapeutics, a clinical-stage cancer drug developer, moved closer to its first major human trial readout while its operating spending climbed. Total quarterly expenses rose 20% from the prior quarter to $22 million by our math, split between $12 million in research and $10 million in overhead. Chief executive Anand Parikh kept the year-end timetable for Phase 2 endometrial cancer results, and cash reserves ended September at $175 million.
| Cash and marketable securities | $174.8M -6.2% from last quarter |
|---|---|
| Research and development spending | $11.7M +27.8% from last quarter |
| Overhead (G&A) spending | $10.4M +12.4% from last quarter |
| Endometrial cancer Phase 2 readout plan | Unchanged expected by year-end 2026 |
⚖️ Verdict: 🟢 Bullish
The story got better because the US Food and Drug Administration granted Fast Track status to its lead drug PIKTOR in endometrial cancer, and human dosing data set the pill schedule right before the year-end readout. One caution: administrative overhead rose 12% from the prior quarter on legal and staff bills, so back-office costs still eat nearly half of total spending two quarters after the February merger.
The question now is whether blocking multiple tumor signals at once shrinks human cancers without causing severe side effects. Either the three-days-a-week pill schedule keeps side effects low enough for patients to stay on treatment, or combined drug toxicity forces dose cuts that weaken the response. The Phase 2 PIK-201 topline data due by the end of December 2026 will tell.
🐂 Bull Case
FDA Fast Track Backs the Lead Cancer Trial
Faeth Therapeutics develops cancer drugs that block multiple growth signals inside a tumor at once. Its main drug candidate is PIKTOR, an oral combination of two drugs called serabelisib and sapanisertib. Chief executive Anand Parikh said the company remains on schedule: "We look forward to reading out topline data from our Phase 2 PIK-201 trial in endometrial cancer by year-end."
Before that readout, US regulators gave the program a boost. The Food and Drug Administration granted Fast Track status to PIKTOR "in combination with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer" who carry specific genetic mutations and already tried standard chemotherapy and immunotherapy.
Fast Track status matters because it lets the biotech developer meet more often with regulators and can speed up future approval reviews. It also validates the target patient group right before the company unveils its first major human trial results.
What to watch: the Phase 2 PIK-201 topline results due by the end of December 2026. Strong tumor shrinkage and manageable side effects would validate the two-drug approach and support talks with the FDA on a registration trial.
Cash Reserves Cover Two Years of Trials
Early-stage drug developers have no product sales, so their survival depends on how fast they spend their cash reserves. When the company acquired the private Faeth business in February 2026, it raised $200 million from life-sciences investors to fund its clinical pipeline.
- Total cash and marketable securities: $174.8 million at the end of September, up from $21.2 million at the end of 2025
- Quarterly cash reduction: $11.6 million by our math, down from $186.4 million in June
- Quarterly net loss: $20.4 million, or $0.79 per share
The company lost $20.4 million on paper, but its actual cash pile shrank by only $11.6 million by our math, helped by $1.7 million in interest income and non-cash items. At that quarterly spending pace, the developer can run for more than two years without raising money, easily covering both of its upcoming cancer readouts.
What to watch: year-end cash and marketable securities in the fourth-quarter report. A quarterly cash drop staying near $12 million to $15 million would confirm that the balance sheet can fund trials well into 2028.
Lab Models Support Multi-Node Drug Design
PIKTOR targets the PAM pathway, a chain of cell signals (PI3K, AKT, and mTOR) that helps tumors grow. "The PAM pathway is dysregulated in up to 50% of solid tumors, and feedback reactivation and resistance mutations may limit single-node inhibitors," Parikh said. Existing drugs block only one link in that chain, which often lets the tumor find a workaround.
During the quarter, scientists presented two sets of supporting data at medical meetings. At a European oncology congress, breast cancer lab models showed PIKTOR blocked key tumor signals at rates "comparable to or exceeding those observed with tested single-node inhibitors". At a second conference, drug-exposure analysis established the exact three-days-a-week pill schedule of 3 mg sapanisertib and 200 mg serabelisib used in the endometrial trial.
Combining two drugs in one regimen often causes high toxicity in human patients, so having human dosing data behind the three-days-a-week schedule reduces a key clinical risk before the December readout.
What to watch: patient discontinuation and dose-reduction rates in the year-end PIK-201 readout. Low dropout rates would prove that patients can tolerate the three-days-a-week schedule long enough for the drug to shrink tumors.
🐻 Bear Case
Operating Spending Climbed 20% in One Quarter
Before the February 2026 merger, the company (then called Sensei Biotherapeutics) was winding down its old drug and cutting staff to save money. Taking over Faeth's two active clinical trials has pushed operating costs much higher.
- Total operating expenses: $22.1 million, up 20.1% from last quarter by our math and up from $4.9 million a year ago
- Research and development (R&D) spending: $11.7 million, up 27.8% from last quarter by our math
- Year-ago R&D spending: $2.5 million, before the Faeth acquisition
Faeth said the jump came from "development costs for PIKTOR and other Faeth programs", including clinical trial, drug manufacturing, and staff expenses. Because the second quarter was the first clean period after the merger, a 28% single-quarter jump in research costs shows the baseline cost of running these trials is still rising fast.
What to watch: fourth-quarter R&D expenses once the Phase 2 endometrial trial finishes its primary analysis. If research spending keeps climbing past $12 million a quarter as one trial wraps up, the company will eat through its cash reserve faster than current levels suggest.
Legal and Staff Costs Keep Overhead High
Biotech investors want their capital spent in the clinic and the lab rather than the back office. While management highlights its clinical progress, general and administrative (G&A) overhead is consuming nearly half of the company's operating budget.
Overhead expenses rose to $10.4 million in the third quarter, up 12.4% from $9.2 million in the second quarter by our math, and more than four times the $2.3 million spent a year ago. The company said the increase was "primarily attributable to higher personnel costs and increased external administrative fees, primarily legal fees".
A jump in legal bills makes sense during the quarter a merger closes, as happened in the spring. Seeing overhead climb another 12% two quarters after the febbraio deal closed cuts against the idea that integration costs are behind it, leaving only 53% of total spending going toward research.
What to watch: fourth-quarter G&A expenses in the year-end report. A drop back below $9 million would show the legal bills were temporary, while another rise would mean permanent corporate overhead is competing with clinical trials for cash.
Breast Cancer Readout Shifted Into 2027
Faeth's second clinical program is PIK-101, a Phase 1b/2 trial testing PIKTOR in patients with hormone-receptor-positive, HER2-negative advanced breast cancer. The company dosed its first patient in this trial in April 2026.
When the company first announced the Faeth buyout in its 2025 annual report, its outlook called for both initiating the breast cancer study and reporting initial topline data by the end of 2026. Since the first quarter of 2026, management has pushed that initial safety and efficacy readout into 2027.
That timeline shift matters because it leaves the entire weight of 2026 on the single endometrial cancer trial in December. If the endometrial data disappoints, investors will have to wait into next year to see whether the drug works better in breast cancer.
What to watch: a specific quarter or half-year target for the PIK-101 breast cancer data in the next update. Narrowing the 2027 window to the first half of the year would show patient enrollment is moving on schedule.
👓 Other Themes
New Executives and Board Members Join
Following its June 2026 name change from Sensei Biotherapeutics, Faeth continued filling out its leadership team this quarter. It hired Deepak Tiwari as senior vice president of technical operations to oversee drug manufacturing and Matt Biegler to lead investor relations, while adding scientific co-founder Karen Vousden and oncology executive Adam Schayowitz to its board of directors.
💲 Other KPIs
Common share count jumped more than fourfold from 5.64 million in the second quarter and 1.26 million a year ago. In June 2026, shareholders approved converting the Series B preferred stock issued in the February merger into common stock. Because the loss was spread across more shares, net loss per share shrank to $0.79 from $2.84 last quarter.
Total liabilities rose 15.7% from $9.58 million at the end of June by our math, and more than doubled from $4.31 million at the end of 2025. The increase tracks the ramp-up in clinical trial activity and outside legal and administrative bills, which leaves more unpaid vendor invoices on the balance sheet at quarter-end.
Other income — mostly interest earned on the company's cash and marketable securities — fell 29.0% from $2.38 million in the second quarter by our math, though it remained far above the $0.28 million earned a year ago. As the biotech group spends down its $174.8 million cash pile to fund trials, this interest cushion will gradually shrink.
🔮 Guidance
Unchanged. Management still plans to report topline clinical results from its Phase 2 endometrial cancer trial before the end of December 2026. The company has held this year-end target across all four quarterly updates since announcing the Faeth acquisition.
Unchanged from last quarter. The developer expects initial safety and efficacy data from its HR+/HER2- breast cancer trial sometime in 2027, having dosed the first patient in April 2026. When the merger was first announced at year-end 2025, the initial target was year-end 2026, before shifting to 2027 in the first quarter.
❓ Key Questions
Why is overhead still rising two quarters after the merger?
General and administrative expenses rose 12.4% from the second quarter to $10.4 million on legal and personnel costs. Investors need to know how much of that legal bill is one-time merger clean-up and what the steady quarterly overhead run rate will be.
How many patients are enrolled in the endometrial readout?
Management promised topline Phase 2 PIK-201 data by year-end 2026 and shared the chosen three-days-a-week dose, but did not disclose how many patients the readout will cover or what tumor response rate it considers a success.
What is left of the old Sensei drug programs?
The release noted that higher PIKTOR spending was partially offset by lower trial costs for legacy Sensei programs. Management has not said whether the old solnerstotug trial is completely closed or still spending money.
Why are 6.8 million preferred shares still unconverted?
Shareholders approved converting the Series B preferred stock into common shares in June 2026, yet $6.8 million of Series B stock remains on the September balance sheet. The company did not explain what holds up the remaining conversion.